• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Apellis Pharmaceuticals Inc (NQ: APLS )

    36.29 -2.07 (-5.40%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,893,673
    Open 38.54
    Bid (Size) 36.46 (1)
    Ask (Size) 37.25 (11)
    Prev. Close 38.36
    Today's Range 36.26 - 39.05
    52wk Range 19.83 - 91.35
    Shares Outstanding 116,457,008
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    What Analysts Are Saying About Apellis Pharmaceuticals Stock
    Via Benzinga
    Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -40.77%
    -40.77%
    1 Month
    -7.54%
    -7.54%
    3 Month
    -39.22%
    -39.22%
    6 Month
    -40.77%
    -40.77%
    1 Year
    -59.33%
    -59.33%

    More News

    Read More
    Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
    Via Benzinga
    In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
    Via Benzinga
    Expert Ratings For Apellis Pharmaceuticals
    Via Benzinga
    Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
    Via Benzinga
    $1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
    Via Benzinga
    APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
    Via Benzinga
    Peering Into Apellis Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    The 5 Stocks Most Sold By Insiders This Year
    Via MarketBeat
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Apellis Pharmaceuticals, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.